Notable Calls @thenotablecalls $GNMK - My take: This looks like a material negative event for Genmark. Potentially significant downside. Reply Retweet Favorite More optionsDetails 22m
The Fly on the Wall @theflynews $LMNX $GNMK Natural Molecular launch a positive for Luminex, says Leerink: Full Story bit.ly/168X46s Details stockwhisperer retweeted 22m
Notable Calls @thenotablecalls $GNMK - Leerink out rather cautious on Genmark after Natural Molecular (~60% of GNMK revs) chose LMNX product over them. Details 22m
Notable Calls @thenotablecalls $GNMK - Leerink out rather cautious on Genmark after Natural Molecular (~60% of GNMK revs) chose LMNX product over them.
Natural Molecular Testing Corporation Launches an Expanded Personalized Medicine Panel Built on Luminex Corporation's xMAP Technology Partnership Advances Pharmacogenomics for Improved Patient Care By Natural Molecular Testing Corporation; Luminex Corporation Published: Tuesday, Jun. 11, 2013 - 6:13 am
SEATTLE, June 11, 2013 -- /PRNewswire/ -- Natural Molecular Testing Corporation (Natural Molecular, NMTC), a privately-owned company providing groundbreaking clinical diagnostic molecular testing and services in the medical genomics field, announced today the launch of their laboratory developed comprehensive Personalized Medicine Panel. This cardiac panel, commercialized by Natural Molecular, is comprised of 42 targets and built using Luminex Corporation's (NASDAQ: LMNX) xMAP® Technology.
"Our goal is to bring the latest advancements in medical science and technology to help clinicians do one simple thing: provide the best possible care for their patients," said Beau R. Fessenden, CEO of Natural Molecular. "By converting to Luminex's xMAP technology, we can improve our throughput and workflow efficiency with more comprehensive and highly sensitive assays that set us apart in the marketplace. The flexibility and high throughput of the Luminex platform combined with the ability to add additional biomarkers make the technology unique and best suited to our expanding needs."
Each year more than 2 million Americans are hospitalized due to adverse drug reactions which lead to an estimated 100,000 deaths.1 Molecular testing allows physicians to diagnose genetic abnormalities in patients, providing guidance in selecting optimal medications and doses of medications while minimizing risk for a wide variety of common conditions such as chronic heart disease and pain.
"We are excited to be expanding our relationship with Natural Molecular in the important area of pharmacogenomics," said Patrick Balthrop, president and CEO of Luminex. "It is valuable for a physician to know whether a specific therapeutic compound will be most beneficial for a particular patient. Through the use of genetic testing, driven by the throughput and scalability of our technology and the unique services of NMTC, our two companies are working together to optimize patient outcomes and lower overall health-care costs. We look forward to expanding opportunities with Natural Molecular, a leader in pharmacogenomic testing."
The financial terms of the multi-year collaboration and license agreement were not disclosed.
About Personalized Medicine Panel Natural Molecular's new comprehensive Personalized Medicine Panel features a simple laboratory workflow based on Luminex's flexible xMAP Technology. Multiplexing a comprehensive set of biomarkers together from a single sample offers significant improvements in testing efficiency saving valuable time and increasing throughput. The panel includes the following:
CYP450 2C19 CYP450 2C9 CYP450 2D6 CYP450 3A4 CYP450 3A5 ABCB1 VKORC1 MTHFR Factor II Factor V Leiden
About Natural Molecular Testing Corporation
Natural Molecular Testing Corporation (NMTC) is a privately-owned, high-complexity molecular testing facility. NMTC provides comprehensive genetic testing solutions that improve patient care through the latest breakthroughs in genomic technology.
For more information about Natural Molecular Testing Corp., visit www.naturalmolecular.com
Cystic Fibrosis 4-way Thrombophilia Warfarin Panel Hep C RVP - Respiratory Virus Panel 3A4/3A5 (RUO) 2C19 (RUO)
The Luminex PR mentions 4 tests as part of NMT's Personalized Medicine Panel where there is overlap with GNMK... 3a4/3A5 and 2C19 which are both RUO (Research Use Only) so not for commercial use yet... and part of the Warfarin and Thrombophilia panel.
GenMark Diagnostics rebounds off lows but remains down over 25% following customer announcement (11.33 -3.80) GenMark Diagnostics is down over 20% today. This morning Natural Molecular Testing Corporation, a privately-owned company providing clinical diagnostic molecular testing and services in the medical genomics field, announced the launch of their laboratory developed comprehensive Personalized Medicine Panel. This cardiac panel, commercialized by Natural Molecular, is comprised of 42 targets and built using Luminex Corporation's (LMNX) xMAP Technology. This can be seen as a negative to GenMark because Natural Molecular is a large customer for GenMark and some of the Luminex technology may overlap with GenMark's products. In it's most recent 10-Q filing GenMark said, "We have one large customer, Natural Molecular Testing Corporation, which accounted for approximately 62% of our total revenue for the three months ended March 31, 2013. " Analysts at Piper Jaffray noted that GenMark recently signed a 4-year rental deal with Natural Molecular, so it is unclear what impact the Luminex deal will have. More clarity should come tomorrow as the company is scheduled to present at 5:00 p.m. EST at the William Blair 33rd Annual Growth Stock Conference.
News 
Market Data 
Discover 
